{"doi":"10.1016/j.mjafi.2021.04.007","title":"Prevalence of isoniazid resistance in cases of rifampicin resistance detected on GeneXpert MTB/RIF assay","abstract":null,"journal":"Medical Journal Armed Forces India","year":2023,"id":639670,"datarank":0.24476759813523072,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.03682344396724709,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.03682344396724709,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":3,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1662087,"name":"Deepu K. Peter","orcid":"0000-0002-4826-5206","position":1,"is_corresponding":false},{"id":1662089,"name":"Vikas Marwah","orcid":null,"position":2,"is_corresponding":false},{"id":678131,"name":"Kunal Kumar","orcid":"0000-0002-1184-4837","position":3,"is_corresponding":false},{"id":1662096,"name":"Gaurav Bhati","orcid":null,"position":4,"is_corresponding":false},{"id":1662085,"name":"C.D.S. Katoch","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Prevalence of isoniazid resistance in cases of rifampicin resistance detected on GeneXpert MTB/RIF assay","abstract":"<h4>Background</h4>The fight against tuberculosis in our country has taken a new shape with the inclusion of rapid nucleic acid amplification tests like GeneXpert MTB/RIF assay which rapidly detects <i>Mycobacterium tuberculosis</i> and rifampicin resistance. Rifampicin resistance detected on GeneXpert has been considered as a sine qua non for the presence of isoniazid resistance and hence classified as multidrug-resistant tuberculosis (MDR-TB). However treatment of rifampicin-resistant, isoniazid-monoresistance, and MDR-TB are different. Our study was done with the aim of identification of the prevalence of isoniazid resistance on culture, in cases which had rifampicin resistance on GeneXpert.<h4>Methods</h4>Pulmonary samples of patients of presumptive tuberculosis were subjected to GeneXpert testing and liquid MGIT (mycobacterium growth indicator tube) culture. On detection of rifampicin resistance on MTB/RIF assay, the patients were included in our study and cultures were followed-up for sensitivity to isoniazid. A total of 76 patients were included.<h4>Results</h4>76 patients of rifampicin resistance on GeneXpert MTB/RIF assay were followed-up for the sensitivity of isoniazid on culture media. Out of the 76 cases, 62 (81.57%) were found to have isoniazid resistance. Out of the 14 patients, the cultures showed no growth in 6, and in the rest, isoniazid was found to be sensitive.<h4>Conclusion</h4>GeneXpert MTB/RIF assay is an excellent modality for the detection of <i>M. tuberculosis</i> and rifampicin resistance. The decision to exclude isoniazid from the treatment regimen in patients with rifampicin resistance should be made only after conducting further molecular/phenotypic tests.","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38144631","pmcid":"PMC10746728","openalex_id":"https://openalex.org/W3174246457","authors":[],"funders":[],"total_grants":0,"fwci":0.0619,"citation_percentile":0.3865791,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"green","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10746728/pdf/main.pdf","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10746728/pdf/main.pdf","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S037712372100109X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S037712372100109X?httpAccept=text/plain","host_type":"publisher"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10746728","host_type":"repository"},{"url":"https://doi.org/10.1016/j.mjafi.2021.04.007","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38144631","host_type":"repository"}],"fields_of_study":["Tuberculosis Research and Epidemiology","Diagnosis and treatment of tuberculosis","Mycobacterium research and diagnosis"],"mesh_terms":[],"keywords":["GeneXpert MTB/RIF","Isoniazid","Rifampicin","Medicine","Tuberculosis","Mycobacterium tuberculosis","Streptomycin","Microbiology","Virology","Drug resistance","Antibiotics","Biology","Pathology","Rifampicin Resistance","Isoniazid Resistance","Genexpert","Multidrug Resistant Tuberculosis","Rifampicin-resistant Tuberculosis"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T01:13:39.358688Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}